- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
COVID-19 Drug Trial: Arthritis, Cancer drug Namiluma, Infliximab tested in UK
Izana Bioscience's Namiluma, a monoclonal antibody already in late-stage tests to treat rheumatoid arthritis and an inflammatory disease called ankylosing spondylitis, is the first of four candidates in the CATALYST trial The second drug, Infliximab (CT-P13), developed by Slough-based Celltrion Healthcare UK, is an anti-tumour necrosis factor (TNF) therapy. It is used to treat eight autoimmune diseases including rheumatoid arthritis and irritable bowel syndrome.
London: Two drugs used to treat inflammatory diseases and cancer are being tested as potential therapies for patients with COVID-19, the Universities of Birmingham and Oxford announced on Wednesday.
Severe cases of COVID-19 are believed to be triggered by an over-reaction of the immune system, known as a cytokine storm, and researchers are investigating whether drugs that suppress certain elements of the immune system can play a role in arresting a rapid escalation of symptoms.
Izana Bioscience's Namiluma, a monoclonal antibody already in late-stage tests to treat rheumatoid arthritis and an inflammatory disease called ankylosing spondylitis, is the first of four candidates in the CATALYST trial.
It targets a cytokine called GM-CSF, which in uncontrolled levels is believed to be a key driver of the excessive and dangerous lung inflammation seen in COVID-19 patients.
The drug is already being tested as a COVID-19 therapy in Italy.
The second drug, Infliximab (CT-P13), developed by Slough-based Celltrion Healthcare UK, is an anti-tumour necrosis factor (TNF) therapy. It is used to treat eight autoimmune diseases including rheumatoid arthritis and irritable bowel syndrome.
Ben Fisher, trial co-clinical investigator from the University of Birmingham, said: "Emerging evidence is demonstrating a critical role for anti-inflammatory drugs in the cytokine storm associated with severe COVID-19 infection.
"In the CATALYST study, we hope to show with a single dose of these kinds of drugs in hospitalised patients that we are able to delay or prevent the rapid deterioration into intensive care and requirement for invasive ventilation in this critical patient group."
Other autoimmune disease drugs that are being tested for their ability to quell the cytokine storm in trials include Regeneron and Sanofi's Kevzara, Roche's Actemra as well as Morphosys and GlaxoSmithKline's otilimab.
Japan's Takeda has a strategic equity stake in Izana.
Read also: NIPER, Hindustan Antibiotic sign MoU for developing 3D antimicrobial face-shields
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751